celecoxib has been researched along with imatinib mesylate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dai, CW; Li, RJ; Liu, DS; Zhang, GS | 1 |
| Gong, FJ; Li, RJ; Zhang, GS | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Heath, J; Kanwar, VS; Krasner, CN; Pearce, JM | 1 |
| Anilkumar, K; Aparna, A; Arunasree, KM; Reddanna, P; Reddy, GV; Roy, KR | 1 |
| Dharmapuri, G; Doneti, R; Kalle, AM; Philip, GH | 1 |
| Atari-Hajipirloo, S; Heydari, A; Kheradmand, F; Nikanfar, S; Noori, F | 1 |
| Blazejczyk, A; Dziegiel, P; Dzimira, S; Hildebrand, W; Krupa, A; Kutkowska, J; Obminska-Mrukowicz, B; Pawlak, A; Rapak, A; Strzadala, L; Wietrzyk, J; Ziolo, E | 1 |
| Deng, XB; Fang, ZG; Lin, DJ; Liu, LL; Liu, Q; Liu, SS; Long, ZJ; Lu, Y; Zou, Y | 1 |
| Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P | 1 |
12 other study(ies) available for celecoxib and imatinib mesylate
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase Inhibitors; Caspases; Celecoxib; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-1; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Pyrazoles; Pyrimidines; S Phase; Sulfonamides | 2006 |
[Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].
Topics: Apoptosis; Benzamides; Celecoxib; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small Cell; Celecoxib; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides; Thalidomide; Vinblastine | 2008 |
Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Benzamides; Celecoxib; Cell Survival; Cells, Cultured; Collagen Type XI; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytochromes c; Dinoprostone; DNA Primers; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sulfonamides | 2008 |
Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Benzamides; Celecoxib; DNA Primers; Humans; Imatinib Mesylate; K562 Cells; Neoplasm Proteins; Piperazines; Pyrazoles; Pyrimidines; ras Proteins; Real-Time Polymerase Chain Reaction; Signal Transduction; Sulfonamides; Wnt Proteins | 2015 |
The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colorectal Neoplasms; Cyclooxygenase 2; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imatinib Mesylate; NF-kappa B; Real-Time Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2016 |
A novel canine B-cell leukaemia cell line. Establishment, characterisation and sensitivity to chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Celecoxib; Cell Line, Tumor; Dexamethasone; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Imatinib Mesylate; Leukemia, B-Cell; Mice; Neoplasm Transplantation; Piroxicam | 2017 |
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
Topics: Adult; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Male; Middle Aged; Necrosis; Neoplasm Staging | 2016 |
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Celecoxib; Cell Cycle Checkpoints; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2016 |